Henry Schein appoints Carole T. Faig as independent director; board expands to 15

HENRY SCHEIN INC

Carole T. Faig appointed effective Dec 13, 2023; will serve until 2024 annual meeting, expected to stand for re-election.
Faig brings 38-year Ernst & Young career, most recently as U.S. Health Leader and West Region Health and Life Sciences Leader.
Board increased size to 15 directors to fill vacancy; Faig is independent and chairs audit committees at three other companies.
Amendment Number Four to Supplemental Executive Retirement Plan approved, effective Jan 1, 2024, allowing joint ventures 50%+ owned to participate.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Carole T. Faig

Director

HSIC · HENRY SCHEIN INC

Effective: 2023-12-13
Filed: December 18, 2023, 6:59 PM ET

the Board increased the size of the Board to fifteen directors and appointed Carole T. Faig as a new independent director to fill the resulting vacancy, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Carole T. Faig was appointed as Director at HENRY SCHEIN INC.

Action: appointed
Role: Director

Exact text from the filing

the Board increased the size of the Board to fifteen directors and appointed Carole T. Faig as a new independent director to fill the resulting vacancy, effective immediately.

View on SEC.gov

HENRY SCHEIN INC filing history →

Source: SEC EDGAR

accession 0001193125-23-297629

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.